Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM

Actinium Pharmaceuticals

Actinium Pharmaceuticals patent portfolio — 20 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2000
Employees
58
Programs
8
Drugs
4
Patents
20
Intelligence · Patents

Actinium Pharmaceuticals patents

20 pharmaceutical patents indexed for Actinium Pharmaceuticals. 1 expire within 24 months.

Actinium Pharmaceuticals has 20 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11981741

    Humanized anti-CD45 antibodies

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11975081

    Bifunctional chelators and conjugates

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11964948

    Bifunctional chelators and conjugates

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11912780

    Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11406724

    Stabilized radiolabeled anti-CD45 immunoglobulin compositions

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11364235

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11292835

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11241512

    Stabilized radio-labeled anti-CD45 immunoglobulin compositions

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10736975

    Infusion administration of conjugated monoclonal antibodies

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10420851

    Stabilized radiolabeled anti-CD45 immunoglobulin compositions

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9790573

    Method for purification of 225AC from irradiated 226RA-targets

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9603954

    Methods for generating radioimmunoconjugates

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9534277

    Method for purification of 225AC from irradiated 226RA-targets

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8349391

    Radium target and method for producing it

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 7374936

    Method and means for site directed therapy

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 6403771

    Method and means for site directed therapy

    Expires Mon Jun 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Actinium Pharmaceuticals have?

20 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Actinium Pharmaceuticals patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.